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Characteristics of Joint Involvement and Relationships
with Systemic Inflammation in Systemic Sclerosis:
Results from the EULAR Scleroderma Trial and
Research Group (EUSTAR) Database
JEROME AVOUAC, ULRICH WALKER, ALAN TYNDALL, ANDRÉ KAHAN, MARCO MATUCCI-CERINIC,
YANNICK ALLANORE, and EUSTAR
ABSTRACT. Objective. To determine the prevalence of and independent factors associated with joint involvement
in a large population of patients with systemic sclerosis (SSc).
Methods. This study was cross-sectional, based on data collected on patients included in the
European League Against Rheumatism (EULAR) Scleroderma Trials and Research (EUSTAR) reg-
istry. We queried this database to extract data regarding global evaluation of patients with SSc and
the presence of any clinical articular involvement: synovitis (tender and swollen joints), tendon fric-
tion rubs (rubbing sensation detected as the tendon was moved), and joint contracture (stiffness of
the joints that decreased their range of motion). Overall joint involvement was defined by the occur-
rence of synovitis and/or joint contracture and/or tendon friction rubs.
Results. We recruited 7286 patients with SSc; their mean age was 56 ± 14 years, disease duration 10
± 9 years, and 4210 (58%) had a limited cutaneous disease subset. Frequencies of synovitis, tendon
friction rubs, and joint contractures were 16%, 11%, and 31%, respectively. Synovitis, tendon fric-
tion rubs, and joint contracture were more prevalent in patients with the diffuse cutaneous subset and
were associated together and with severe vascular, muscular, renal, and interstitial lung involvement.
Moreover, synovitis had the highest strength of association with elevated acute-phase reactants taken
as the dependent variable.
Conclusion. Our results highlight the striking level of articular involvement in SSc, as evaluated by
systematic examination in a large cohort of patients with SSc. Our data also show that synovitis, joint
contracture, and tendon friction rubs are associated with a more severe disease and with systemic inflam-
mation. (First Release June 15 2010; J Rheumatol 2010;37:1488–501; doi:10.3899/jrheum.091165)
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Systemic sclerosis (SSc) is a severe connective tissue dis-
ease characterized by vascular, immune, and fibrotic
changes in the skin and some internal organs1. SSc is incur-
able and can influence all aspects of an individual’s life,
including the performance of everyday occupations2.
Impaired hand function, characterized by decreased hand
mobility, reduced dexterity, and decreased grip force, has
been clearly identified by patients with SSc as a major
source of difficulty in their activities of daily living3. Joint
involvement has been shown to strongly contribute to
impaired hand function in SSc, leading to disability and
impaired quality of life and highlighting the importance of
joint involvement in SSc4-8. Studies have shown the striking
level of radiological hand involvement at the articular, bone,
and soft tissue levels in SSc (Table 1)4,9-12. This high preva-
lence of hand and wrist joint pathology was confirmed by
ultrasonography in a recent study performed with 45
patients with SSc (Table 1)13. Moreover, the usefulness of
magnetic resonance imaging (MRI) was additionally
emphasized in the accurate diagnosis and characterization of
SSc-associated hand arthropathy (Table 1)14,15. Although
these studies ought to increase the understanding of osteo-
1489Avouac, et al: EUSTAR database results
articular involvement, few data are available on the preva-
lence of clinical joint involvement, which has not yet been
defined accurately. At some time in the disease course,
patients with SSc may develop joint involvement. This man-
ifests clinically as arthralgia, arthritis, joint contracture,
and/or tendon sheath involvement. Joint involvement may
even predate the development of classical features of the
disease16,17. Joint symptoms have been noted in different
series in 12% to 66% of patients at the time of diagnosis and
in 24% to 97% of patients at some time during the course of
their illness4,16. Histological evidence of inflammation with
lymphocytic and plasma-cell infiltration has been found in
up to 66% of synovial biopsies from patients with SSc4.
This wide variation, and disparities in the reported preva-
lence of clinical features, as well as the scarce data available
about their association with other disease measure-
ments/phenotypes, requires clarification in a large popula-
tion of patients with SSc. We aimed to determine the point
prevalence of joint involvement (synovitis, joint contrac-
ture, and tendon friction rubs) in a large population of
Europeans with SSc and to identify disease-phenotype
associations.
MATERIALS AND METHODS
The European League Against Rheumatism (EULAR) Scleroderma Trials
and Research (EUSTAR) Joint Study was cross-sectional, based on data
collected on patients with SSc who were included in the EUSTAR registry.
This database was launched in June 2004 and documents a multinational,
prospective, and open SSc cohort. Since 2004, 150 participating medical
centers entered consecutive patients into a registry and all data into a spe-
cific database, which was locked for this study in April 2008. The structure
and Minimal Essential Dataset (MEDS) of the EUSTAR database have
been described18-20. The MEDS was constructed in consensus by the
EUSTAR members, and covers demographic aspects, disease duration,
organ involvement, and laboratory data. Baseline data collected during the
first patient visit to a EUSTAR center were analyzed for the purpose of our
study. All patients included in either database granted their informed con-
sent to participate, and appropriate institutional ethics committees approved
the research program.
The data regarding the presence of articular involvement was assessed
as “yes” or “no” in the following manner: (1) synovitis (defined by tender
Table 1. Hand involvement in systemic sclerosis, assessed by radiographs, ultrasonography, and magnetic
resonance imaging (MRI).
Hand Condition Radiography Ultrasonography MRI
and Joint Avouac9, Baron4, La Montagna10, Brun11, Cuomo13, Low14,
n = 120 n = 38 n = 76 n = 41 n = 45 n = 17
Joint involvement, n (%)
Erosion 25 (21) 15 (40) 8 (10.5) ND 5 (11) 7 (41)
Wrist 17 4 ND ND 1 2
MCP 9 9 ND ND 4 5
PIP 10 3 ND ND 0 2
DIP 18 7 ND ND 0 0
Joint space narrowing, n (%) 35 (28) 13 (34) ND 10 (24) 8 (18) ND
Wrist 13 2 13 (17) ND 0 ND
MCP 12 2 ND ND 8 ND
PIP 14 4 31 (41) ND 2 ND
DIP 25 12 41 (54) ND 0 ND
Synovitis, n (%) NA NA NA NA 22 (49) 8 (47)
Wrist 2 2
MCP 15 5
PIP 12 1
DIP 1 0
Synovial proliferation, n (%) NA NA NA NA 19 (42) ND
Wrist 2 ND
MCP 12 ND
PIP 2 ND
DIP 0 ND
Tenosynovitis, n (%) NA NA NA NA ND 8 (47)
Flexor ND 7
Extensor ND 3
Bone involvement, n (%)
Radiological demineralization 28 (23) 16 (42) 12 (16) 7 (17) ND ND
Acroosteolysis 26 (22) 14 (37) 22 (29) 11 (27) ND ND
Bone edema NA NA NA NA NA 9 (53)
Soft tissue involvement, n (%)
Flexion contracture 32 (27) ND 31 (41) ND NA ND
Calcinosis 28 (23) 19 (50) 45 (59) 18 (44) 12 (27) ND
ND: no data; NA: not applicable; MRI: magnetic resonance imaging; MCP: metacarpophalangeal joint; PIP:
proximal interphalangeal joint; DIP: distal interphalangeal joint.
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and swollen joints); (2) tendon friction rubs (defined by a leathery, rubbing,
“squeaking” sensation detected as the tendon was moved actively or pas-
sively); and (3) joint contracture (defined by stiffness of the joint that
decreased range of motion and prevented full extension). Overall joint
involvement was defined, for the purpose of our study, by the occurrence
of synovitis and/or joint contracture and/or tendon friction rubs in at least 1
area or 1 joint.
Global evaluation of patients with SSc was also assessed and extracted
from the MEDS data (Figure 1)18. Global evaluation was based on the col-
lection of clinical variables, including distinction of the cutaneous subset of
the disease according to the LeRoy criteria21, disease duration (date of first
non-Raynaud symptom), and presence of active or past digital ulcerations.
Pulmonary involvement was recorded as present if pulmonary fibrosis was
seen on plain chest radiographs and/or by the presence of abnormal respi-
ratory function tests (carbon monoxide diffusion capacity). Pulmonary
hypertension was recorded as present by the finding of systolic pulmonary
artery pressure (SPAP) > 40 mm Hg on an echocardiogram. Renal involve-
ment was recorded as present if there was a history of hypertensive renal
crisis or by the presence of proteinuria (+ or more on a urinalysis dipstick).
Muscle involvement was recorded as present if muscle weakness and/or
elevated creatine phosphokinase (CPK) was present. Inflammatory markers
were recorded as present if the erythrocyte sedimentation rate (ESR) was >
28 mm/h or by C-reactive protein > 10 mg/l. The following serological tests
were recorded as present or absent: antinuclear antibodies (ANA), anticen-
tromere antibodies (by immunofluorescence on HEp-2 cells), and anti-
topoisomerase I antibodies (counter immunoelectrophoresis and/or immuno-
diffusion).
Statistical analysis. All data are presented as mean (SD) for continuous
variables and numbers (percentages) for categorical variables, unless stat-
ed otherwise. Data were statistically analyzed using chi-square tests for dif-
ferences in frequency and the Student’s t-test for comparison between 2
normally distributed continuous variables. We applied a Bonferroni correc-
tion for multiple comparisons. To this end, we divided 0.05 by the number
of disease characteristics tested (17 sets of variables) and obtained a cor-
rected probability value of 0.003. Thus, probability value ≤ 0.003 was con-
sidered statistically significant. A multivariate stepwise logistic regression
Figure 1. Items of the Minimal Essential Dataset (MEDS). From Walker, et al. Ann
Rheum Dis 2007;68:754-6318; with permission.
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analysis was also performed for all variables identified with p ≤ 0.10 uni-
variately, with calculation of OR estimates and 95% CI (OR and probabil-
ity value were not provided by the software when not significant)19. The
OR is a measure of effect size, used as a descriptive statistic in logistic
regression analysis, describing the strength of association between 2 data
values. Unlike other measures of association for paired data such as the rel-
ative risk, the OR treats the 2 variables being compared symmetrically, and
can be estimated using some types of nonrandom samples. In this model,
probability value < 0.05 was considered statistically significant.
RESULTS
Study population.We included 7286 successive patients with
SSc, of whom 6266 (86%) were women. The mean age of the
patients was 56 ± 14 years and the mean disease duration was
10 ± 9 years; 4210 had the limited cutaneous subtype, 2393
the diffuse cutaneous subtype, and it was not possible to clas-
sify 683 patients according to the LeRoy criteria21. The other
patient characteristics are provided in Table 2.
Prevalence of articular manifestations. The point preva-
lence of synovitis was 16% (1191/7286). Tendon friction
rubs and joint contracture were found in the whole SSc pop-
ulation in 802/7286 (11%) and 2264/7286 (31%) patients,
respectively (Figure 2A). The number of patients with any
of these 3 features, defining overall joint involvement, was
2025/7286 (28%).
Association of articular involvement with other subpheno-
types. The detailed results of association between some
articular involvement (respectively, synovitis, joint contrac-
ture, and tendon friction rubs) and other subsets of patients
with SSc are provided in Tables 3 to 8.
The frequency of synovitis was significantly higher in
patients with the diffuse cutaneous subset compared to the
limited cutaneous subtype (484/2393, 20%, vs 570/4210,
13.5%; p < 0.05; Figure 2B). In the whole population of
patients with SSc, using multivariate stepwise logistic
regression, synovitis was associated with markers of severe
vascular (elevated SPAP > 40 mm Hg) and muscular (mus-
cle weakness) involvement (Table 3). The presence of syn-
ovitis was also associated with elevated acute-phase reac-
tants (Table 3). It is noteworthy that, in another multivariate
model with elevated acute-phase reactants taken as the
dependent variable, synovitis had the highest strength of
association, with an OR of 2.10, 95% CI 1.67–2.64.
Subgroup analyses according to the cutaneous subset
showed that patients with synovitis and either limited or dif-
fuse cutaneous SSc were more likely to experience severe
disease and systemic inflammation (Table 3).
Synovitis was present in patients with SSc in all disease
stages: indeed, 460/1191 (39%) patients with SSc with syn-
ovitis had disease duration < 5 years, 345/2196 (29%) had
disease duration between 5 and 10 years, and 386/2669
(32%) had disease duration > 10 years. Subgroup analyses
according to disease duration also showed that the likeli-
hood of the diffuse cutaneous subset was significantly high-
er only in the subgroup of patients with synovitis and early
disease (date of first non-Raynaud symptom, < 5 years).
Moreover, associations identified in the whole SSc popula-
tion, between synovitis and criteria of severe disease and
systemic inflammation, were found in all disease stages
(Table 4).
As expected, the prevalence of tendon friction rubs was
significantly higher in patients with the diffuse cutaneous
subset (486/2393, 20%, vs 260/4210, 6%; p < 0.05; Figure
2B). In the whole population of patients with SSc, this
symptom indicated the existence of a severe vascular, inter-
stitial lung, and renal involvement (Table 5). In patients with
the diffuse cutaneous involvement, tendon friction rubs
were noted most often in younger patients and early in the
disease. The subset of patients with tendon friction rubs and
diffuse cutaneous SSc was more likely to experience severe
muscular, vascular, and kidney involvement. Patients with
limited skin thickening who had friction rubs also experi-
enced a more severe disease (digital ulcers, pulmonary
fibrosis, muscle weakness) and had higher frequency of
antitopoisomerase-1 antibodies (37% vs 19%), which may
suggest that these patients may represent a subset of indi-
viduals with “subclinical” or “aborted” diffuse SSc (Table
5). Altogether this suggests that tendon friction rubs can be
regarded as a marker of severity of SSc.
Tendon friction was noted in all disease stages, but tend-
ed to occur more often in early disease: 322/802 (40%)
patients with SSc with tendon friction rubs had a disease
duration < 5 years, 213/802 (27%) between 5 and 10 years,
and 267/802 (33%) > 10 years. Sensitivity analyses accord-
Table 2. Characteristics of patients presenting with systemic sclerosis who
were included in the EUSTAR database up to April 2008.
Characteristic Patients with SSc,
n = 7286
Age, mean ± SD, yrs 56 ± 14
Men/women, n (%) 1020 (14)/6266 (86)
Disease duration, mean ± SD, yrs 10 ± 9
Cutaneous subtype, n (%)
Limited 4210 (58)
Diffuse 2393 (33)
Not classified 683 (9)
Raynaud phenomenon, n (%) 6946 (95)
Digital ulceration, n (%) 2291 (31)
Muscle weakness, n (%) 1950 (27)
Pulmonary fibrosis, n (%) 2607 (36)
Elevated systolic pulmonary artery pressure, n (%) 1756 (24)
Renal crisis, n (%) 160 (2)
Positive antinuclear antibodies, n (%) 6617 (91)
Positive antitopoisomerase-1 antibodies, n (%) 2293 (31)
Positive anticentromere antibodies, n (%) 2396 (33)
Elevated creatine phosphokinase (CPK), n (%) 581 (8)
Elevation of acute-phase reactants, n (%) 2153 (29)
Proteinuria, n (%) 435 (6)
Active disease according to European score, n (%) 2118 (29)
EUSTAR: European League Against Rheumatism Scleroderma Trials and
Research; SSc: systemic sclerosis.
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ing to disease duration revealed that the likelihood of tendon
friction rubs was higher in the patients with diffuse cuta-
neous SSc in all disease stages, but with a higher OR in the
subset of patients with early disease (OR 2.58 in patients
with disease duration < 5 years vs OR 1.54 and 2.09, respec-
tively, for patients with disease duration between 5 and 10
years and > 10 years; Table 6). Moreover, patients with early
friction rubs were more likely to experience severe disease,
regardless of the disease stage (Table 6).
Like synovitis and tendon friction rubs, the prevalence of
joint contracture was significantly higher in the diffuse cuta-
neous subtype (1167/2393, 49%, vs 975/4210, 23%; p <
0.05; Figure 2B). In the whole SSc population, joint con-
tracture was associated with severe vascular and interstitial
Figure 2. A. Prevalence of joint involvement in the whole population of patients with SSc. B. Prevalence of
joint involvement in populations with the diffuse and limited cutaneous disease subsets. *Diffuse versus limit-
ed cutaneous subsets, p < 0.05.
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lung involvement (Table 7). Patients with joint contracture
and either diffuse or limited cutaneous SSc were more like-
ly to experience severe vascular and muscular disease, as
well as to have elevated acute-phase reactants.
Joint contracture was found in patients with SSc at all dis-
ease stages: 745/2264 (33%) patients with joint contracture
had disease duration < 5 years, 538/2264 (24%) had disease
duration between 5 and 10 years, and 981/2264 (43%) had
disease duration > 10 years. The likelihoods of diffuse cuta-
neous subset and criteria for severe vascular, muscular, and
interstitial disease were significantly higher in patients with
joint contracture, regardless of disease duration (Table 8).
Overall joint involvement (defined by the presence of
synovitis and/or joint contracture and/or tendon friction
rubs) was significantly more prevalent in multivariate analy-
ses in patients with the diffuse cutaneous subtype
(1005/2393 patients, 42%, vs 1020/4210 patients, 24%; p <
0.05). It was associated with markers of severe vascular
(digital ulcers with OR 1.80, 95% CI 1.60–2.03; and elevat-
ed SPAP > 40 mm Hg with OR 1.62, 95% CI 1.42–1.84),
muscular (muscle weakness with OR 1.65, 95% CI
1.45–1.87), and interstitial lung involvement (pulmonary
fibrosis with OR 1.14, 95% CI 1.01–1.28). Joint involve-
ment also reflected disease activity and it was associated
with elevated acute-phase reactants (OR 1.66, 95% CI
1.46–1.88).
It is noteworthy that these symptoms were more likely
to occur together. Synovitis, taken as the dependent vari-
able in our multivariate model, was associated with the
presence of joint contracture (OR 1.81, 95% CI 1.55–2.11)
and tendon friction rubs (OR 2.21, 95% CI 1.82–2.67).
Tendon friction rubs were associated with synovitis (OR
2.31, 95% CI 1.91–2.71) and joint contracture (OR 3.04,
95% CI 2.54–3.65), respectively, and joint contracture was
associated with the presence of synovitis (OR 1.75, 95%
CI 1.49–2.05) and tendon friction rubs (OR 2.89, 95% CI
2.39–3.50), respectively (Tables 3, 5, and 7). These associ-
ations remained significant in the different subgroup
analyses, within cutaneous subsets and disease duration
(Tables 3 to 8).
Table 3. Disease phenotype associations in patients with SSc with or without synovitis.
Patient Whole SSc Population, Patients with Diffuse Cutaneous Patients with Limited
Characteristic n = 7286 Subtype, n = 2393 Cutaneous Subtype, n = 4210
With Without p Stepwise With Without p Stepwise With Without p Stepwise
Synovitis, Synovitis, Regression, Synovitis, Synovitis, Regression, Synovitis, Synovitis, Regression
n = 1191 n = 6095 OR n = 484 n = 1909 OR n = 570 n = 3640 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 58 ± 16 58 ± 15 0.8 NS 54.7 ± 14 55.5 ± 15 0.3 NS 60.4 ± 16 60.0 ± 17 0.6 NS
Females (%) 1029 (86) 5237 (86) 0.88 NS 389 (80) 1504 (79) 0.5 NS 516 (91) 3275 (90) 0.9 NS
Disease duration, 10 ± 8 9 ± 8 0.61 NS 7.8 ± 9 8 ± 10 0.6 NS 9.4 + 9 13.3 ± 11 0.004* 0.78
mean ± SD, yrs (0.57–0.90)
Friction rub, n (%) 291 (24) 511 (8) < 0.0001* 2.21 173 (36) 313 (16) < 0.0001* 2.07 93 (16) 167 (5) < 0.0001* 2.67
(1.82–2.67) (1.62–2.65) (1.96–3.63)
Joint contracture, n (%) 587 (49) 1677 (27) < 0.0001* 1.81 302 (62) 865 (45) < 0.0001* 1.38 240 (42) 735 (20) < 0.0001* 2.12
(1.55–2.11) (1.09–1.74) (1.72–2.62)
Raynaud phenomenon, 1144 (96) 5802 (95) 0.36 NS 466 (96) 1822 (95) 0.7 NS 551 (97) 3488 (96) 0.5 NS
n (%)
Digital ulceration, n (%) 468 (39) 1823 (30) < 0.0001* NS 241 (50) 741 (39) < 0.0001* NS 202 (35) 993 (27) 0.0001* NS
Muscle weakness, n (%) 488 (41) 1462 (24) < 0.0001* 1.47 264 (55) 606 (32) < 0.0001* 1.95 189 (33) 715 (20) < 0.0001* 1.53
(1.26–1.72) (1.56–2.44) (1.23–1.91)
Pulmonary fibrosis, n (%) 505 (42) 2102 (34) < 0.0001* NS 266 (55) 951 (50) 0.09* NS 193 (34) 1023 (28) < 0.0001* NS
Elevated systolic 408 (34) 1348 (22) < 0.0001* 1.49 185 (38) 453 (24) < 0.0001* 1.51 182 (32) 770 (21) < 0.0001* 1.52
pulmonary artery (1.28–1.73) (1.20–1.91) (1.22–1.89)
pressure, n (%)
Renal crisis, n (%) 41 (3.5) 119 (2) 0.002* NS 29 (6) 72 (4) 0.04* NS 8 (1) 41 (1) 0.6 NS
Positive antinuclear 1094 (92) 5523 (91) 0.97 NS 437 (90) 1734 (91) 0.9 NS 516 (91) 3347 (92) 0.3 NS
antibodies, n (%)
Positive 497 (42) 1796 (29) < 0.0001* 1.29 319 (66) 998 (52) < 0.0001* NS 144 (25) 714 (20) 0.002* NS
antitopoisomerase-1 (1.08–1.53)
antibodies, n (%)
Positive anticentromere 286 (24) 2110 (35) < 0.0001* NS 29 (6) 111 (6) 0.9 NS 230 (40) 1821 (50) < 0.0001* NS
antibodies, n (%)
Elevated CPK, n (%) 120 (10) 461 (8) 0.005* NS 73 (15) 221 (12) 0.05* NS 30 (5) 174 (5) 0.7 NS
Elevation of acute- 541 (45) 1612 (26) < 0.0001* 1.49 271 (56) 690 (36) < 0.0001* 1.67 218 (38) 802 (22) < 0.0001* 1.77
phase reactants, n (%) (1.28–1.74) (1.34–2.07) (1.43–2.17)
Proteinuria, n (%) 107 (9) 328 (5) < 0.0001* NS 61 (13) 152 (8) 0.02* NS 31 (5) 141 (4) 0.08 NS
NS: not significant; CPK: creatine phosphokinase; SSc: systemic sclerosis. * Variables included for the multivariate stepwise logistic regression analysis.
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DISCUSSION
Our results highlight the striking level of articular involve-
ment in SSc, as evaluated by systematic examination in a
large cohort of patients. Overall joint involvement is more
prevalent in patients with the diffuse cutaneous subtype, and
is associated with more severe disease phenotype and sys-
temic inflammation. Our data also show that synovitis, joint
contracture, and tendon friction rubs are more likely to
occur together.
Joint involvement has been reported to occur in a wide
proportion of patients with SSc4. Many distinct abnormali-
ties have been recognized4,10,22, but their precise prevalence
in a large population of patients with SSc has not yet been
accurately determined. Thus, the EUSTAR database,
enabled by the major efforts of multiple medical centers,
offers a unique opportunity to study these specific compli-
cations in a large population of patients with SSc. The
recruitment of patients among EUSTAR centers ensured a
representative population, although geographical variation
of disease manifestations was recently reported23. More-
over, data were standardized with the help of the MEDS and
were collected in tertiary centers highly active in the field of
SSc, a situation that markedly increased their quality and
accuracy.
The prevalence of clinical synovitis has not yet been
determined accurately. One study systematically assessed
articular involvement in 38 patients with SSc4. Tenderness,
stress pain, or effusions were found in 61% of patients.
Effusions, found in 10 patients (29%), were small and pre-
dominant in the knees. The pattern was polyarticular in
61%, oligoarticular in 22%, and monoarticular in 17%. In
the EUSTAR database, synovitis was found in 1191/7286
(16%) patients with SSc, underlining that synovial involve-
ment may occur in SSc, although generalized arthralgia and
stiffness are the more common presentations4,12,24. This
synovial involvement has been recently reported by ultra-
sonography and MRI, which showed their usefulness for
accurate diagnosis and characterization of synovitis of the
hands and wrists of patients with SSc (Table 1)13-15.
The presence of synovitis may be related to an overlap
Table 4. Disease characteristics associated with synovitis according to disease duration.
Patients with Disease Duration, Patients with Disease Duration Patients with Disease Duration
Characteristic < 5 Years, n = 2421 Between 5 and 10 Years, n = 2196 > 10 Years, n = 2669
With Without p Stepwise With Without p Stepwise With Without p Stepwise
Synovitis, Synovitis, Regression, Synovitis, Synovitis, Regression, Synovitis, Synovitis, Regression
n = 460 n =1961 OR n = 345 n = 1851 OR n = 386 n = 2283 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 55.5 ± 11 56.2 ± 12 0.4 NS 56.3 ± 14 56.8 ± 12 0.6 NS 60.9 ± 15 61.3 ± 16 0.5 NS
Females (%) 368 (80) 1582 (81) 0.5 NS 306 (89) 1579 (85) 0.3 NS 355 (92) 2076 (91) 0.8 NS
Diffuse cutaneous, 233 (51) 784 (39) < 0.0001* 1.96 114 (33) 521 (28) 0.002* NS 137 (35) 604 (26) 0.001* NS
subtype, n (%) (1.45–2.51)
Friction rub, n (%) 121 (26) 201 (10) < 0.0001* 2.51 66 (19) 147 (8) < 0.0001* 1.82 104 (27) 163 (7) < 0.0001* 2.84
(1.87–3.39) (1.33–2.42) (2.05–3.93)
Joint contracture, n (%) 214 (46) 531 (27) < 0.0001* 1.75 147 (43) 391 (21) < 0.0001* 2.04 226 (58) 755 (33) < 0.0001* 1.81
(1.37–2.24) (1.53–2.73) (1.41–2.32)
Raynaud phenomenon, 433 (94) 1845 (94) 0.9 NS 329 (95) 1696 (92) 0.8 NS 382 (99) 2261 (99) 0.2 NS
n (%)
Digital ulceration, n (%) 162 (35) 534 (27) 0.002* NS 120 (35) 520 (28) 0.005* NS 186 (48) 769 (34) < 0.0001* NS
Muscle weakness, n (%) 189 (41) 505 (26) < 0.0001* NS 127 (37) 416 (22) < 0.0001* 1.73 172 (45) 541 (24) < 0.0001* 1.89
(1.29–2.30) (1.47–2.44)
Pulmonary fibrosis, n (%) 178 (29) 618 (32) 0.01* NS 149 (43) 655 (35) 0.0008* NS 178 (46) 829 (36) 0.0005* NS
Elevated systolic 155 (34) 400 (20) < 0.0001* 1.81 103 (30) 388 (21) 0.0001* NS 150 (39) 560 (24) < 0.0001* 1.39
pulmonary artery (1.40–2.32) (1.07–1.75)
pressure, n (%)
Renal crisis, n (%) 21 (4) 54 (3) 0.04* NS 15 (4) 31 (1.5) 0.02* NS 5 (6) 34 (1.5) 0.9 NS
Positive antinuclear 404 (88) 1701 (87) 0.8 NS 314 (91) 1704 (92) 0.8 NS 376 (97) 2118 (93) 0.2 NS
antibodies, n (%)
Positive 202 (44) 636 (32) < 0.0001* NS 145 (42) 537 (29) < 0.0001* 1.91 150 (39) 623 (27) 0.0003* NS
antitopoisomerease-1 (1.42–2.57)
antibodies, n (%)
Positive anticentromere 97 (21) 582 (30) 0.0008* NS 72 (21) 616 (33) 0.0003* NS 117 (30) 912 (40) 0.0001* NS
antibodies, n (%)
Elevated CPK, n (%) 69 (15) 218 (11) 0.04* NS 34 (10) 128 (7) 0.1* NS 17 (4) 115 (5) 0.1* NS
Elevation of acute- 237 (52) 549 (28) < 0.001* 2.29 133 (39) 447 (24) < 0.0001* 1.60 171 (44) 616 (27) < 0.0001* 1.49
phase reactants, n (%) (1.81–2.90) (1.20–2.14) (1.16–1.91)
Proteinuria, n (%) 52 (11) 128 (6) 0.0004* NS 24 (7) 99 (5) 0.2 NS 31 (8) 101 (4) 0.01* NS
NS: not significant; CPK: creatine phosphokinase. * Variables included for the multivariate stepwise logistic regression analysis.
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with rheumatoid arthritis (RA) or, more probably, to the
existence of primary erosive arthropathy specific to
SSc9,25-27. Recent data indicate that the overlap of SSc and
RA is unusual. The prevalence of SSc-RA overlap is 1% to
5% and its incidence is 5%17,28-30. Moreover, 1 study from
our group showed in a population of 120 patients with SSc
a point prevalence of radiographic erosive arthritis of 18%,
while only 2 patients with SSc (2%) with radiographic
arthritis fulfilled the American College of Rheumatology
criteria for classic RA9. These data are supported by the low
frequency of antibodies against cyclic citrullinated peptide
in SSc (prevalence 1.5% to 8%), which have the highest
specificity for the diagnosis of RA31-33.
Patients with synovitis and early disease were more like-
ly to experience diffuse cutaneous thickening. This observa-
tion raises the possibility of using synovitis in patients with
early SSc to identify those with potential risk of developing
the diffuse cutaneous subset, which has a more fulminant
course. We also found that the likelihoods of severe vascu-
lar and muscular involvement were higher in patients with
synovitis, regardless of their cutaneous subset or their dis-
ease duration. Thus, synovitis could be a risk factor of bad
prognosis in SSc, and we suggest that all patients be
screened for synovitis immediately after the diagnosis of
SSc. The validation of synovitis as a predictive factor of the
diffuse cutaneous subset and bad prognosis is now under
investigation in the prospective followup of patients with
SSc included in the EUSTAR database.
We found that elevation of acute-phase reactants, reflect-
ing systemic inflammation, was strongly associated with
synovitis. This suggests that joint involvement has a close
relationship with systemic inflammation in SSc9. This is
supported by the existence of inflammatory cell infiltration,
associated with focal microvascular obliteration and fibrin
deposition, on synovial biopsies performed on patients with
SSc34. Further studies are warranted to determine whether
Table 5. Disease phenotype associations in patients with SSc with or without tendon friction rubs.
Whole SSc Population, Patients with Diffuse Cutaneous Patients with Limited
Characteristic n = 7286 Subtype, n = 2393 Cutaneous Subtype, n = 4210
With Without p Stepwise With Without p Stepwise With Without p Stepwise
TFR, TFR, Regression, TFR, TFR, Regression, TFR, TFR, Regression
n = 802 n = 6484 OR n = 486 n = 1907 OR n = 260 n = 3950 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 56 ± 15 58 ± 18 0.001* NS 51 ± 13 55 ± 15 0.002* 0.69 59 ± 15 60 ± 19 0.3 NS
(0.48–0.85)
Females (%) 666 (83) 5600 (86) 0.001* NS 376 (77) 1517 (80) 0.3 NS 236 (91) 3555 (90) 0.8 NS
Disease duration, 9 ± 10 10 ± 11 0.53 NS 4 ± 8 9 ± 10 0.0001* 0.56 10 ± 11 10 ± 12 0.9 NS
mean ± SD, yrs (0.32–0.83)
Synovitis, n (%) 291 (36) 900 (14) < 0.0001* 2.31 173 (36) 311 (16) < 0.0001* 2.20 93 (36) 477 (12) < 0.0001* 2.90
(1.91–2.79) (1.69–2.87) (2.18–3.96)
Joint contracture, n (%) 528 (66) 1736 (27) < 0.0001* 3.04 365 (75) 802 (42) < 0.0001* 3.15 139 (53) 836 (21) < 0.0001* 2.66
(2.54–3.65) (2.44–4.06) (2.01–3.54)
Raynaud phenomenon, 765 (95) 6181 (95) 0.93 NS 467 (96) 1821 (95) 0.7 NS 250 (96) 3789 (96) 0.9 NS
n (%)
Digital ulceration, n (%) 383 (48) 1908 (29) < 0.0001* 1.21 260 (53) 722 (38) < 0.0001* 1.25 107 (41) 1088 (28) < 0.0001* 1.38
(1.01–1.44) (1.02–1.78) (1.03–1.83)
Muscle weakness, n (%) 367 (46) 1583 (24) < 0.0001* 1.42 245 (50) 625 (33) < 0.0001* 1.32 103 (40) 801 (20) < 0.0001* 1.84
(1.18–1.70) (1.03–2.14) (1.38–2.46)
Pulmonary fibrosis, n (%) 399 (50) 2208 (34) < 0.0001* 1.22 278 (57) 939 (49) 0.003* NS 106 (41) 1110 (28) < 0.0001* 1.49
(1.02–1.46) (1.12–1.98)
Elevated sPAP, n (%) 272 (34) 1484 (23) < 0.0001* NS 175 (36) 463 (24) < 0.0001* NS 78 (30) 874 (22) 0.02* NS
Renal crisis, n (%) 36 (4) 124 (2) < 0.0001* NS 27 (6) 74 (4) 0.1* NS 7 (3) 42 (1) 0.03* NS
Positive ANA, n (%) 740 (92) 5877 (91) 0.78 NS 444 (91) 1727 (91) 0.4 NS 234 (90) 3629 (92) 0.6 NS
Positive 382 (48) 1911 (29) < 0.0001* NS 291 (60) 1026 (54) 0.001* NS 95 (37) 763 (19) 0.0001* 1.32
antitopoisomerease-1 (1.15–1.72)
antibodies, n (%)
Positive anticentromere 130 (16) 2266 (35) < 0.0001* NS 21 (4) 119 (6) 0.2 NS 101 (39) 1950 (49) 0.001* NS
antibodies, n (%)
Elevated CPK, n (%) 115 (14) 466 (7) 0.005* NS 80 (16) 214 (11) 0.001* NS 21 (8) 183 (5) 0.002* NS
Elevation of acute- 377 (47) 1776 (27) < 0.0001* NS 267 (55) 696 (36) < 0.0001* NS 95 (37) 923 (23) < 0.0001* NS
phase reactants, n (%)
Proteinuria, n (%) 92 (11) 343 (5) < 0.0001* 1.38 64 (13) 149 (8) 0.0002* 1.22 17 (7) 155 (4) 0.05* NS
(1.02–1.87) (1.01–1.79)
TFR: tendon friction rubs; NS: not significant; CPK: creatine phosphokinase; ANA: antinuclear antibodies; SSc: systemic sclerosis; sPAP: systolic pulmonary artery pressure.
* Variables included for the multivariate stepwise logistic regression analysis.
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.
1496 The Journal of Rheumatology 2010; 37:7; doi:10.3899/jrheum.091165
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2010. All rights reserved.
joint involvement is the main contributor to systemic
inflammation in SSc (as in RA).
Tendon friction rubs are also common during the disease
course, leading to a coarse and palpable crepitus, which is
very specific to SSc. These rubs were found in 11% of this
large cohort and were more prevalent in patients with the
diffuse cutaneous subset and early disease. However, their
prevalence was lower than previously reported in a large
American study of 1305 patients with SSc. In that study,
rubs were found in 28% (368/1305) of patients35. This dif-
ferent point prevalence could be partly explained by the
higher proportion of patients with the diffuse cutaneous sub-
set in the American study (49% vs 33% in our study).
As expected, we found that friction rubs were associated
with the diffuse cutaneous subtype in all disease stages, but
with higher OR in the subset of patients with early disease.
This observation underlines the strength of association
between rubs and diffuse cutaneous SSc in patients with
early disease, as observed in the American study35.
In patients with the diffuse cutaneous subset and with
early disease, the presence of tendon friction rubs was asso-
ciated with signs of severe vascular, muscular, and renal
involvement, as reported10,15,24. This is also supported by a
study that assessed the clinical and prognostic significance
of palpable tendon friction rubs in patients with SSc. The
authors showed strong correlations between the presence of
tendon friction rubs and typical features of diffuse cuta-
neous SSc: more severe skin thickening, more frequent heart
and kidney involvement, and decreased survival35.
One original point raised by our results is the identifica-
tion of patients with rubs and limited cutaneous subtype or
with rubs and late disease as new groups at risk of severe
disease. It is noteworthy that patients with friction rubs and
limited cutaneous disease had a higher frequency of anti-
topoisomerase I antibodies. This observation suggests that
these patients may represent a subset of individuals with
“subclinical” or “aborted” diffuse SSc. Altogether, our data
suggest that searching for friction rub should be a routine
Table 6. Disease characteristics associated with tendon friction rubs, according to disease duration.
Patients with Disease Duration, Patients with Disease Duration Patients with Disease Duration
Characteristic < 5 Years, n = 2421 Between 5 and 10 Years, n = 2196 > 10 Years, n = 2669
With Without p Stepwise With Without p Stepwise With Without p Stepwise
TFR, TFR, Regression, TFR, TFR, Regression, TFR, TFR, Regression
n = 322 n = 2099 OR n = 213 n = 1983 OR n = 267 n = 2402 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 51 ± 10 56 ± 11 0.001* 0.71 55 ± 13 57 ± 10 0.1* NS 58 ± 12 61 ± 14 0.009* NS
(0.48–0.92)
Females (%) 238 (74) 1712 (82) 0.003* NS 186 (87) 1699 (86) 0.9 NS 242 (91) 2189 (91) 0.6 NS
Diffuse cutaneous, 230 (71) 787 (37) < 0.0001* 2.58 126 (59) 509 (26) < 0.0001* 1.54 130 (49) 611 (25) < 0.0001* 2.09
subtype, n (%) (1.87–3.53) (1.09–2.18) (1.52–2.89)
Synovitis, n (%) 121 (38) 339 (16) < 0.0001* 2.80 66 (31) 279 (14) < 0.0001* 2.54 104 (39) 282 (12) < 0.0001* 2.85
(2.03–3.81) (1.97–3.67) (2.04–3.97)
Joint contracture, n (%) 196 (61) 549 (26) < 0.0001* 2.41 146 (69) 392 (20) < 0.0001* 4.55 186 (70) 795 (33) < 0.0001* 3.05
(1.78–3.23) (3.20–6.47) (2.18–4.27)
Raynaud phenomenon, 311 (97) 1967 (94) 0.1* NS 204 (96) 1821 (92) 0.6 NS 250 (94) 2393 (99) 0.1* NS
n (%)
Digital ulceration, n (%) 125 (39) 571 (27) 0.0001* 1.22 112 (53) 528 (27) < 0.0001* 1.65 146 (55) 809 (34) < 0.0001* 1.47
(1.04–1.65) (1.18–2.32) (1.07–2.01)
Muscle weakness, n (%) 150 (47) 544 (26) < 0.0001* 1.37 95 (45) 448 (23) < 0.0001* 1.61 122 (46) 591 (25) < 0.0001* 1.54
(1.02–1.86) (1.14–2.27) (1.12–2.13)
Pulmonary fibrosis, n (%) 149 (46) 647 (31) < 0.0001* NS 120 (56) 684 (34) < 0.0001* 1.55 130 (49) 877 (37) < 0.0001* NS
(1.11–2.18)
Elevated sPAP, n (%) 102 (32) 453 (22) 0.0006* NS 66 (31) 425 (21) 0.005* NS 104 (39) 606 (25) < 0.0001* 1.60
(1.16–2.21)
Renal crisis, n (%) 17 (5) 58 (3) 0.02* NS 9 (4) 37 (2) 0.03* NS 10 (4) 29 (1) 0.02* NS
Positive ANA, n (%) 296 (92) 1809 (86) 0.7 NS 192 (90) 1826 (92) 0.8 NS 252 (94) 2242 (93) 0.8 NS
Positive sc170 164 (51) 674 (32) < 0.0001* NS 103 (48) 579 (29) < 0.0001* NS 115 (43) 658 (27) < 0.0001* NS
antibodies, n (%)
Positive ACA, n (%) 39 (12) 640 (30) < 0.0001* NS 32 (15) 656 (33) < 0.0001* NS 59 (22) 970 (40) < 0.0001* NS
Elevated CPK, n (%) 72 (22) 215 (10) < 0.0001* NS 26 (12) 136 (7) 0.007* NS 17 (6) 115 (5) 0.09* NS
Elevation of acute- 176 (55) 610 (29) < 0.0001* NS 98 (46) 482 (24) < 0.0001* NS 103 (39) 684 (28) 0.0007* NS
phase reactants, n (%)
Proteinuria, n (%) 42 (13) 138 (7) 0.0002 NS 23 (11) 100 (5) 0.0008* 1.90 27 (10) 105 (4) 0.0001* NS
(1.07–3.36)
TFR: tendon friction rubs; NS: not significant; CPK: creatine phosphokinase; ANA: antinuclear antibodies; ACA: anticentromere antibodies; sPAP: systolic pulmonary artery
pressure. * Variables included for the multivariate stepwise logistic regression analysis.
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part of the physical examination also in patients with the
limited cutaneous subset or in a late disease stage. The pre-
dictive value of tendon friction rubs in these new groups at
risk will be further investigated with the ongoing prospec-
tive followup of patients entered in the EUSTAR database.
Joint contracture results from joint destruction, turning
into ankylosis, and fibrotic changes in the skin, the hallmark
of SSc and a source of functional disability6,7. We confirm
that joint contracture is associated with the diffuse cuta-
neous subset in all disease stages, known to have the higher
fibrotic propensity, and with pulmonary fibrosis. This asso-
ciation, taken with the association we reported between flex-
ion contracture and Health Assessment Questionnaire find-
ings9, emphasizes the greater impairment of hand function
in the diffuse subgroup, as reported by Brower and Poole6.
We did not find any association in multivariate analysis
between the serum levels of antitopoisomerase I antibodies
and joint flexion contracture, in contrast with recently pub-
lished data that have suggested a high correlation36.
Our data show that synovitis, joint contracture, and ten-
don friction rubs are strongly associated in the multivariate
analysis. This suggests an interdependence of these symp-
toms in the development of articular involvement and fur-
ther disability. This may also indicate a shared mechanism
in their development.
The frequency of any articular symptoms was 28%
(2025/7286) in this large cohort, which is consistent with
other findings4,10,12 and highlights the frequency and the
burden of articular involvement in SSc. Indeed, after life-
threatening complications, important articular involvement
may weigh on the quality of life of patients with SSc, as has
been demonstrated5,9. As for synovitis, tendon friction rubs,
or joint contracture, the occurrence of any joint symptoms
was associated with a severe disease phenotype, suggesting
that joint involvement could be a potential marker of disease
severity.
Our study is limited by its observational design, and any
pathogenic link emerging from this type of study should be
Table 7. Disease phenotype associations in patients with SSc with or without joint contracture (JC).
Whole SSc Population, Patients with Diffuse Cutaneous Patients with Limited
Characteristic n = 7286 Subtype, n = 2393 Cutaneous Subtype, n = 4210
With Without p Stepwise With Without p Stepwise With Without p Stepwise
JC, JC, Regression, JC, JC, Regression, JC, JC, Regression
n = 2264 n = 5022 OR n = 1167 n = 1226 OR n = 975 n = 3235 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 57 ± 16 58 ± 17 0.01* NS 53 ± 14 56 ± 15 0.04* NS 58 ± 15 62 ± 16 0.001* NS
Females (%) 1902 (84) 4364 (87) 0.0001* NS 932 (80) 961 (78) 0.4 NS 855 (88) 2936 (91) 0.1* NS
Disease duration, 11 ± 8 9 ± 10 0.03* NS 6 ± 7 9 ± 8 0.01* 0.47 10 ± 9 12 ± 13 0.001* NS
mean ± SD, yrs (0.38–0.81)
Friction rub, n (%) 528 (23) 274 (5) < 0.0001* 2.89 365 (31) 121 (10) < 0.0001* 3.16 133 (14) 134 (4) < 0.0001* 2.67
(2.39–3.50) (2.42–4.12) (1.98–3.61)
Synovitis, n (%) 587 (26) 604 (12) < 0.0001* 1.75 302 (26) 182 (15) < 0.0001* 1.53 233 (24) 337 (10) < 0.0001* 2.01
(1.49–2.05) (1.18–1.98) (1.68–2.59)
Raynaud phenomenon, 2172 (96) 4774 (95) 0.2 NS 1118 (96) 1170 (95) 0.9 NS 933 (96) 3106 (96) 0.1* NS
n (%)
Digital ulceration, n (%) 1023 (45) 1268 (25) < 0.0001* 1.93 592 (51) 390 (32) < 0.0001* 1.88 397 (41) 798 (25) < 0.0001* 1.85
(1.69–2.19) (1.54–2.30) (1.55–2.19)
Muscle weakness, n (%) 868 (38) 1080 (21) < 0.0001* 1.41 504 (43) 358 (29) < 0.0001* 1.38 300 (31) 604 (19) < 0.0001* 1.47
(1.22–1.62) (1.12–1.71) (1.21–1.79)
Pulmonary fibrosis, 1050 (46) 1557 (31) < 0.0001* 1.23 623 (53) 594 (48) 0.02* NS 371 (38) 845 (26) < 0.0001* NS
n (%) (1.08–1.39)
Elevated sPAP, n (%) 715 (32) 1041 (21) < 0.001* 1.38 373 (32) 259 (21) < 0.0001* 1.47 287 (29) 665 (21) < 0.0001* 1.30
(1.19–1.58) (1.17–1.84) (1.07–1.57)
Renal crisis, n (%) 72 (3) 88 (2) 0.0001* NS 53 (5) 48 (4) 0.5 NS 16 (2) 33 (1) 0.1* NS
Positive antinuclear 2103 (93) 4514 (90) 0.06* NS 1080 (93) 1091 (89) 0.03* NS 878 (90) 2985 (92) 0.9 NS
antibodies, n (%)
Positive 975 (43) 1318 (26) < 0.0001* NS 688 (59) 629 (51) 0.0004* NS 261 (27) 597 (18) < 0.0001* NS
antitopoisomerease-1
antibodies, n (%)
Positive anticentromere 406 (18) 1990 (40) < 0.0001* 0.56 48 (4) 92 (8) 0.0009* 0.59 340 (35) 1711 (53) < 0.0001* 0.50
antibodies, n (%) (0.47–0.66) (0.39–0.90) (0.42–0.59)
Elevated CPK, n (%) 239 (11) 342 (7) 0.005* NS 166 (14) 128 (10) 0.007* NS 70 (7) 134 (4) 0.0001* NS
Elevation of acute- 931 (41) 1222 (24) < 0.0001* 1.48 547 (47) 408 (33) < 0.0001* 1.49 328 (34) 690 (21) < 0.0001* 1.56
phase reactants, n (%) (1.29–1.70) (1.12–1.82) (1.30–1.87)
Proteinuria, n (%) 186 (8) 249 (5) < 0.0001* NS 120 (10) 93 (8) 0.02* NS 48 (5) 124 (4) 0.1* NS
NS: not significant; CPK: creatine phosphokinase; sPAP: systolic pulmonary artery pressure. * Variables included for the multivariate stepwise logistic regression analysis.
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regarded cautiously. We expect the prospective followup of
this cohort to strengthen the associations we found and to
assess articular involvement as a marker and a predictor of
disease severity. The association between joint involvement
and elevated SPAP should be regarded cautiously, as there
was no definite pulmonary arterial hypertension confirma-
tion with right-heart catheterization. The difficulty of detect-
ing synovitis because of overlying cutaneous thickening and
the difficulty of distinguishing synovitis from joint pain
with swollen fingers may have biased the prevalence of syn-
ovitis. Moreover, most of our patients were postmenopausal
women and were therefore prone to develop osteoarthritis,
which could be characterized by tender and swollen joints.
We could not rule out the possibility of such an arthropathy,
unrelated to SSc, occurring in our patients.
The brevity and shallowness of the data collected in the
MEDS form did not allow us to assess the precise distribu-
tion of joint involvement [number and localization of ten-
der/swollen joints and friction rubs, joint(s) involved in joint
contracture]. This contrasts with studies performed on a lim-
ited number of patients, but with a more in-depth view of the
extent, frequency, and degree of synovitis, friction rubs, and
contracture coupled with radiographs, ultrasound, and MRI
results.
We also could not assess the contribution of articular
manifestations to disability, or the influence of other meas-
urements on joint involvement, such as therapies (cortico-
steroids, disease-modifying drugs), specific antibodies
(rheumatoid factors, anti-citrullinated peptide antibodies/
second generation), or potential overlap with other diseases,
such as RA. The results of radiographs were not collected in
the database, which prevented us from correlating clinical
and radiological joint involvement.
We did not perform any analysis between joint involve-
ment and disease activity. The European disease activity
index, proposed by the European Scleroderma Study Group,
was collected in the MEDS and recorded as present if it dis-
played a score ≥ 337. However, the calculation of the final
Table 8. Disease characteristics associated with joint contracture (JC), according to disease duration.
Patients with Disease Duration < 5 years, Patients with Disease Duration Between Patients with Disease Duration
Characteristic n = 2421 5 and 10 Years, n = 2196 > 10 Years, n = 2669
With Without p Stepwise With Without p Stepwise With Without p Stepwise
JC, JC, Regression, JC, JC, Regression, JC, JC, Regression
n = 745 n = 1676 OR n = 538 n = 1658 OR n = 981 n = 1688 OR
(95% CI) (95% CI) (95% CI)
Age, mean ± SD, yrs 55 ± 12 56 ± 13 0.1* NS 54 ± 11 57 ± 14 0.03 NS 60 ± 15 62 ± 17 0.03 NS
Females (%) 566 (76) 1384 (83) < 0.0001* NS 457 (85) 1428 (86) 0.1* NS 879 (90) 1552 (92) 0.1* NS
Diffuse cutaneous 467 (63) 550 (33) < 0.0001* 2.36 294 (55) 341 (21) < 0.0001* 2.01 406 (41) 335 (20) < 0.0001* 1.93
subtype, n (%) (1.87–2.98) (1.56–2.60) (1.54–2.41)
Synovitis, n (%) 214 (29) 246 (15) < 0.0001* 1.86 147 (27) 198 (12) < 0.0001* 1.82 226 (23) 160 (9) < 0.0001* 1.84
(1.43–2.41) (1.34–2.48) (1.42–2.38)
Tendon friction rub, n (%) 196 (26) 126 (8) < 0.0001* 2.32 146 (27) 392 (24) < 0.0001* 4.18 186 (19) 81 (5) < 0.0001* 3.19
(1.72–3.15) (2.92–5.99) (2.28–2.48)
Raynaud phenomenon, 713 (96) 1565 (93) 0.3 NS 522 (97) 1503 (91) 0.3 NS 937 (96) 1606 (95) 0.7 NS
n (%)
Digital ulceration, n (%) 295 (40) 401 (24) < 0.0001* 1.75 251 (47) 389 (23) < 0.0001* 1.91 477 (49) 478 (28) < 0.0001* 1.89
(1.39–2.20) (1.50–2.44) (1.55–2.30)
Muscle weakness, n (%) 316 (42) 378 (23) < 0.0001* 1.61 198 (37) 345 (21) < 0.0001* 1.52 354 (36) 359 (21) < 0.0001* NS
(1.27–2.05) (1.17–1.97)
Pulmonary fibrosis, 326 (44) 470 (28) < 0.0001* NS 269 (50) 535 (32) < 0.0001* NS 455 (46) 552 (33) < 0.0001* 1.23
n (%) (1.02–1.54)
Elevated sPAP, n (%) 236 (32) 319 (19) < 0.0001* 1.58 162 (30) 329 (20) < 0.0001* NS 317 (32) 393 (23) < 0.0001* 1.30
(1.23–2.03) (1.05–1.60)
Renal crisis, n (%) 36 (5) 39 (2) 0.002* NS 16 (3) 30 (2) 0.08* NS 20 (2) 19 (1) 0.1* NS
Positive ANA, n (%) 683 (92) 1422 (85) 0.6 NS 503 (93) 1515 (91) 0.08* NS 917 (93) 1577 (93) 0.5 NS
Positive scl70 352 (47) 486 (29) < 0.0001* NS 239 (44) 443 (27) < 0.0001* NS 384 (39) 389 (23) < 0.0001* NS
antibodies, n (%)
Positive ACA, n (%) 96 (13) 583 (35) < 0.0001* 0.46 80 (15) 608 (37) < 0.0001* 0.50 230 (22) 799 (47) < 0.0001* 0.64
(0.34–0.62) (0.37–0.68) (0.52–0.80)
Elevated CPK, n (%) 146 (20) 141 (8) < 0.0001* 1.41 57 (11) 105 (6) 0.001* NS 36 (4) 96 (6) 0.3 NS
(1.02–1.94)
Elevation of acute- 347 (47) 439 (26) < 0.0001* NS 239 (44) 341 (21) < 0.0001* 1.53 345 (35) 442 (26) < 0.0001* 1.69
phase reactants, n (%) (1.17–1.99) (1.37–2.07)
Proteinuria, n (%) 81 (11) 99 (6) 0.002* NS 42 (8) 81 (5) 0.01* NS 63 (6) 69 (4) 0.009* NS
NS: not significant; CPK: creatine phosphokinase; sPAP: systolic pulmonary artery pressure; ANA: antinuclear antibodies; ACA: anticentromere antibodies. * Variables includ-
ed for the multivariate stepwise logistic regression analysis.
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score included synovitis and increased ESR. As it was not
possible to analyze this index independently from these 2
items, we did not perform any analysis between joint
involvement and disease activity. The current development
of the MEDS Online database, with a huge collection of data
and a prospective followup, will allow us to complete this
first evaluation.
Our results highlight the striking level of articular
involvement in SSc, as evaluated by systematic examination
in a large cohort of patients with SSc. Our study also shows
that articular involvement is associated with more severe
disease and with systemic inflammation. This observation
suggests that the subset of patients with SSc who have artic-
ular symptoms may be regarded as a severe disease sub-
group, and the predictive values of articular involvement on
outcomes remain be determined.
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